Polydex Pharmaceuticals Limited (OTCMKTS:POLXF – Get Rating) shares were down 4.2% during mid-day trading on Friday . The stock traded as low as $0.73 and last traded at $0.74. Approximately 2,100 shares traded hands during trading, a decline of 45% from the average daily volume of 3,792 shares. The stock had previously closed at $0.77.
Polydex Pharmaceuticals Stock Down 4.2 %
The company has a debt-to-equity ratio of 0.02, a current ratio of 5.89 and a quick ratio of 3.81. The stock has a market capitalization of $2.53 million, a PE ratio of -3.69 and a beta of 0.28. The company has a 50 day moving average price of $0.79 and a 200-day moving average price of $0.82.
Polydex Pharmaceuticals (OTCMKTS:POLXF – Get Rating) last posted its earnings results on Thursday, September 15th. The company reported ($0.09) earnings per share (EPS) for the quarter. Polydex Pharmaceuticals had a negative net margin of 16.58% and a negative return on equity of 11.89%. The business had revenue of $1.09 million for the quarter.
About Polydex Pharmaceuticals
Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. The company also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. It primarily offers dextran and derivative products, including iron dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry.
- Get a free copy of the StockNews.com research report on Polydex Pharmaceuticals (POLXF)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Polydex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polydex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.